Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXY111A in Hepato-Pancreato-Biliary Neoplasia
NCT02528526Phase 2Unknown
- Sponsor
- University of Zurich
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of myo-inositol trispyrophosphate in pancreatic neoplasm, hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and 1 more, sponsored by University of Zurich. Primary endpoint: Safety and tolerability at 10 weeks. Status: unknown.
02
Drugs
myo-inositol trispyrophosphate
03
Conditions
pancreatic neoplasmhepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)colorectal neoplasms
Beyond the preview
Go deeper on NCT02528526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528526.